Orchard Therapeutics plc
ORTX evidence brief
What we can confirm
- BioSniper Score:
- 8.7 / 10
- Lead Asset:
- libmeldy (Approved)
What it means
What to watch
Prepared research question
What matters most for ORTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
libmeldy (Approved)
Next Catalyst
—
Financial data as of Sep 30, 2023.
Tracking 5 pipeline candidates · 5 clinical trials for Orchard Therapeutics plc.
Run Orchard Therapeutics plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Orchard Therapeutics plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.52 · 0% dilution
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Orchard Therapeutics plc's lead drug candidate?
Orchard Therapeutics plc's most advanced tracked candidate is libmeldy (Approved) for early-onset metachromatic leukodystrophy (MLD).
Who is the CEO of Orchard Therapeutics plc?
Health Affairs is the chief executive officer of Orchard Therapeutics plc (ORTX).
What therapeutic areas does Orchard Therapeutics plc focus on?
Orchard Therapeutics plc develops therapies across Rare Disease, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.